Long-term follow-up of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
|
|
- Morgan Gilmore
- 5 years ago
- Views:
Transcription
1 & 2013 International Society of Nephrology Long-term of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear Michael Walsh 1, Alina Casian 2, Oliver Flossmann 3, Kerstin Westman 4, Peter Höglund 5, Charles Pusey 6 and David R.W. Jayne 2 on behalf of the European Vasculitis Study Group (EUVAS) 1 Departments of Medicine (Nephrology), and Clinical Epidemiology and Biostatistics, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada; 2 Lupus and Vasculitis Clinic, Addenbrooke s Hospital, Cambridge, UK; 3 Renal Department, Royal Berkshire Hospital, Reading, UK; 4 Department of Nephrology, University Hospital Malmo, Malmo, Sweden; 5 Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden and 6 Department of Medicine, Imperial College London, Hammersmith Hospital, London, UK Patients with antineutrophil cytoplasm antibody associated vasculitis (AAV) requiring dialysis at diagnosis are at risk for developing end-stage renal disease (ESRD) or dying. Shortterm results of a trial comparing plasma exchange () to intravenous methylprednisolone () suggested improved renal recovery. Here we conducted long-term to see if this trend persisted. A total of 137 patients with newly diagnosed AAV and a serum creatinine over 500 lmol/l or requiring dialysis were randomized such that 69 received and 68 received in addition to cyclophosphamide and oral glucocorticoids. The patients were followed for a median of 3.95 years. In each group there were 35 deaths, while 23 and 33 patients developed ESRD. The hazard ratio for compared to IV MeP for the primary composite outcome of death or ESRD was 0.81 (95% confidence interval ). The hazard ratio for all-cause death was 1.08 with a subhazard ratio for ESRD of 0.64 (95% confidence interval ). Thus, although short-term results with are encouraging, the long-term benefits remain unclear. Further research is required to determine the role of in AAV. Given the poor outcomes of patients with severe AAV, improved treatment is urgently needed. Kidney International (2013) 84, ; doi: /ki ; published online 24 April 2013 KEYWORDS: plasma exchange; randomized controlled trial; vasculitis Correspondence: Michael Walsh, Departments of Medicine (Nephrology), and Clinical Epidemiology and Biostatistics, St Joseph s Hospital, McMaster University, Marian Wing, Hamilton, Ontario, Canada L8N 4A6. lastwalsh1975@gmail.com Received 15 June 2012; revised 22 January 2013; accepted 31 January 2013; published online 24 April 2013 Granulomatosis polyangiitis (formerly Wegener s granulomatosis) and microscopic polyangiitis are associated with antineutrophil cytoplasm antibodies and are collectively referred to as the antineutrophil cytoplasm antibody associated vasculitides (AAV). Although treatment with immunosuppressive drugs and glucocorticoids has improved outcomes for patients with AAV, those with severely reduced kidney function at diagnosis are at high risk of death and end-stage renal disease (ESRD). 1 Rapid and complete initial disease control may improve the clinical outcomes of patients with severe AAV by reducing the burden of organ scarring that occurs early in the course of disease. However, given that patients with severe AAV are also at high risk of serious infections, adjuvant therapies must be minimally toxic. 2 Both plasma exchange () and pulse intravenous methylprednisolone () are potential treatments that may enhance remission induction without serious toxicity. The MEPEX trial compared with as adjuvants to cyclophosphamide and oral prednisolone in patients with a new diagnosis of AAV and a serum creatinine 4500 mmol/l or requiring dialysis. 3 The primary outcome for MEPEX was renal recovery defined as a creatinine o500 mmol/l or dialysis independence within 12 months of randomization. MEPEX demonstrated a 50% relative reduction in the need for dialysis at 12 months for participants that received compared with those who received IV methylprednisolone. 3 We hypothesized that such a substantial reduction in early dialysis dependency represented dramatic improvement in disease control and likely arrested organ damage, which would result in significant improvement in medium and long-term prognosis. However, the MEPEX trial had a higher-than-anticipated mortality rate and recent metaanalyses call into question whether is truly effective at reducing the clinically important endpoints of death and ESRD for patients with severe AAV. 4 We conducted a study of Kidney International (2013) 84,
2 the long-term outcomes of patients from the MEPEX trial, to determine whether the benefits of on renal function in the short term resulted in a long-term lower risk of death or ESRD (ISRCTN and NCT ). RESULTS One hundred and thirty-seven patients were enrolled and followed for a median of 3.95 years for a total of 515 patientyears at risk. Patients enrolled in the MEPEX trial have been previously described (Table 1). Patients with granulomatosis polyangiitis and those with alveolar hemorrhage were slightly more common in the group than in the group. Table 1 Baseline characteristics of patients enrolled in the MEPEX trial (n ¼ 68) (n ¼ 69) Age, median (IQR) 66 (59 71) 67 (60 70) Female, n (%) 24(35) 28(49) Granulomatosis with polyangiitis, n (%) 25(37) 17(25) Anti-PR3 positive, n (%) 31(46) 27(39) Creatinine at entry, median (IQR) 732 ( ) 701 ( ) BVAS at entry, median (IQR) 19.5 ( ) 19 (15 23) Alveolar hemorrhage present, n (%) 18(26.5) 13(18.8) Abbreviations: BVAS, Birmingham Vasculitis Activity Score; IQR, 25th to 75th percentile interquartile range;, intravenous methylprednisolone;, plasma exchange; PR3, proteinase Screened 137 Randomized Included in original trial 12-month dialysis independence outcome 45 Completed long-term 19 Deaths before 12-month 5 Lost after 12-month 52 Included in original trial 12-month dialysis independence outcome 41 Completed long-term 69 Included for analysis 68 Included for analysis 16 Deaths before 12-month 10 Lost after 12-month Figure 1 Flow diagram. Flow diagram of patients., intravenous methylprednisolone;, plasma exchange. One hundred and twenty-two patients (90%) had their vital status ascertained in long-term. Fifteen (5 and 10 ) patients did not complete the long-term (Figure 1). Three patients from the group developed ESRD and one from the same group relapsed before being lost to long-term. No patients from the group developed ESRD, died, or relapsed before being lost to long-term. Patients did not differ significantly with respect to therapy used after the end of the original study period (Table 2). Outcomes Table 3 summarizes the clincial outcomes. Of the 70 patients (51%) that died, 35 (51%) were in the group and 35 (51%) were in the group. Fifty-six patients (41%) developed ESRD (23 vs. 33 ) and 86 (63%) developed the composite endpoint of death or ESRD (40 vs. 46 ). Three in the group compared with 1 in the group died of pulmonary hemorrhage, whereas 9 in the group compared with 15 in the group died of infection. Infections were the most common cause of death (24 of 70 deaths (34%)) and deaths attributed to active vasculitis were uncommon (2 of 70 deaths (3%)). Overall, there was no statistically significant difference in the distribution of causes of death (P ¼ 0.80), although infectious causes were more common in the group (15 (43%)) than in the group (9 (26%); Table 3). Only 26 patients (10 vs. 16 ) suffered a relapse of vasculitis. We did not find an effect of on the composite endpoint (hazard ratio (HR), 0.81; 95% confidence interval (CI), ; P ¼ 0.32) or on the all-cause death (HR, 1.08; 95% CI, ; P ¼ 0.75; Figures 2 and 3). Similarly, in competing-risk models in which death was the competing risk, we did not find an effect of on ESRD (sub-hr, 0.64; 95% CI, ; P ¼ 0.08; Figure 4). Twenty-six patients had a relapse, 10 (14.4%) in the group and 16 (20.5%) in the group (sub-hr, 0.56; 95% CI, ; P ¼ 0.14). Similarly, there was no demonstrable difference between groups with an sub-hr for renal relapse of 1.14 (95% CI, ; P ¼ 0.80) for compared with (Table 4). Sensitivity analyses that adjusted for other prognostic factors did not materially alter the assessment of compared with, with respect to the primary composite outcome or the outcomes of ESRD, death, or relapse (i.e., in no analyses was one treatment superior to the other). At 5 years, the median creatinine in the 37 patients alive and not on dialysis with a measure was 167 mmol/l ( ) and was not different between patients treated with (176 ( )) compared with those treated with (158 ( )). No difference between groups was detected when either comparing the 5-year keratinize levels (P ¼ 0.43 by Kreskas Wallis test) or after adjusting for baseline creatinine with analysis of covariance (mean difference, 398 Kidney International (2013) 84,
3 Table 2 Therapy after the end of the orignal trial period for patients in the MEPEX trial Cyclophosphamide, n (%) Azathioprine, n (%) Prednisone, n (%) Months after randomization P-value P-value P-value (7) 5 (12) (64) 23 (55) (82) 32 (76) (5) 1 (3) (59) 20 (51) (73) 26 (67) (8) 2 (5) (44) 14 (37) (54) 25 (66) (8) 5 (14) (37) 13 (36) (53) 20 (56) (6) 4 (12) (41) 12 (36) (47) 15 (45) 0.9, intravenous methylprednisolone;, plasma exchange. P-values obtained from two-tailed w 2 -test. Table 3 Long-term primary and secondary outcomes by treatment group Outcome, n ¼ 68 (%), n ¼ 69 (%) HR (95% CI) P-value Death or ESRD 46 (68) 40 (58) 0.81 ( ) 0.32 Death 35 (51) 35 (51) 1.08 ( ) 0.75 ESRD a 33 (49) 23 (33) 0.64 ( ) 0.08 Relapse a 16 (21) 10 (14) 0.56 ( ) 0.14 Abbreviations: ESRD, end-stage renal disease; HR, hazard ratio;, intravenous methylprednisolone;, plasma exchange group. a Subhazard ratio presented. P-value based on Cox regression or competing risk regression model. Table 4 Causes of death over the course of long-term followup Primary cause of death, n (%) (n ¼ 35) (n ¼ 35) Vasculitis (%) 1 (2.9) 1 (2.9) Pulmonary hemorrhage (%) 3 (8.6) 1 (2.9) Infection (%) 9 (25.7) 15 (42.9) Cardiovascular (%) 6 (17.1) 4 (11.4) ESRD (%) 1 (2.9) 1 (2.9) Cancer (%) 3 (8.6) 2 (5.7) Other 12 (34.3%) 11 (31.4%) Proportion free of ESRD or death Number at risk Time (years) Figure 2 Kaplan Meier curve of composite outcome. Kaplan Meier curve of the composite outcome of end-stage renal disease (ESRD) or death according to randomization to treatment with intravenous methylprednisolone () or plasma exchange (). 1 Abbreviations: ESRD, end-stage renal disease;, intravenous methylprednisolone;, plasma exchange. There was no difference in the overall distribution of cause of death (P ¼ 0.80). Proportion dead mmol/l; 95% CI, 44 to 101 mmol/l; P ¼ 0.43). Similarly, there were no significant differences between groups when comparing the last measured keratinize values of 70 patients who were alive at the end of the first year and were not on dialysis by the study end (median 221 ( ) in the group compared with 192 ( ) in the group; P ¼ 0.41) Number at risk Time (years) DISCUSSION We assessed the long-term outcomes of patients with severe AAV that were treated with either or as initial adjuvant therapy. After a median of almost 4 years, there was no evidence of a net difference between and in clinical outcomes. Furthermore, over half of patients with severe AAV at diagnosis died, and almost twothirds had either developed ESRD or died. The outcomes for patients with severe AAV continue to be very poor. Figure 3 Kaplan Meier curve of deaths. Kaplan Meier curve of deaths in patients with severe antineutrophil cytoplasm antibody associated vasculitis randomized to intravenous methylprednisolone () or plasma exchange (). The MEPEX trial was designed to assess renal recovery and was found to be superior to at 12 months. 3 In our extended study, we focused on ESRD and survival. If truly reduces ESRD, it seems logical that longer-term mortality should also be reduced given the Kidney International (2013) 84,
4 Cumulative incidence of ESRD Time (years) Figure 4 Cumulative incidence curve. Cumulative incidence curve of end-stage renal disease (ESRD) in patients with severe antineutrophil cytoplasm antibody associated vasculitis randomized to intravenous methylprednisolone () or plasma exchange () when death is treated as a competing risk. strong association between ESRD and death. The fact that this was not seen could be due to several reasons. First, it is possible that ESRD in severe AAV does not share the same relationship with death as seen in other conditions (i.e., ESRD caused by AAV is not strongly associated with death). This is possible as patients with severe, acute AAV do not accumulate chronic morbidity before initiating ESRD as, e.g., patients with chronic diabetes mellitus do. 5 Second, it is possible that the effect of early in AAV results in a true reduction in ESRD, but that this effect is obscured over time by other non-aav morbidities causing death in both groups. This results in a low signal-to-noise ratio in a small trial. Given the advanced age of the population at the start of the trial, this is certainly possible. This finding could also be explained if reduces ESRD but also increases mortality via a mechanism independent of ESRD (e.g., infection) or if there were a bias towards initiating dialysis in the group. Finally, it must be considered that the early benefits observed were random error. Other studies have suggested that 1500 randomized patients are optimally required to reliably demonstrate whether is effective in reducing death and ESRD in patients with AAV. 4 is frequently advocated as the standard of care for patients with pulmonary hemorrhage or advanced renal failure secondary to AAV. 6,7 Our study demonstrated that death from pulmonary hemorrhage was infrequent in both and -treated patients despite similar occurrence at trial entry in both groups. Further, although the results are encouraging regarding the prevention of ESRD, we did not demonstrate that the reduction in ESRD lead to a reduction in mortality. These findings raise uncertainty regarding the net benefit of as a first-line treatment in patients with severe manifestations of AAV, and this uncertainty is compounded when the relative paucity of information regarding clinical outcomes is considered. Previous studies have suggested that even when we consider all randomized trials of in AAV, there is insufficient evidence to make reliable conclusions. 4 Perhaps the most important finding of our study is not that did not materially improve the incidence of ESRD or death compared with for patients with severe AAV. The most important finding is that half the study cohort died within 5 years from the time of diagnosis, with many of the survivors requiring dialysis. Further, the most frequent cause of death was infectious in nature, whereas very few were due to active vasculitis. Pateints with severe AAV have several important risk factors for infections including: the use of chronic immunosuppression, the placement of central intravenous catheters, uremia/dialysis dependency, and gammaglobulin depletion from. These complicated risk factors result both from the treatment for AAV being toxic (i.e., immunosuppressive) and being inadequately effective (i.e., need for ongoing immunosuppression and failure to prevent ESRD). As such, research to reduce treatment toxicity while improving disease control both in the short- and long term is urgently needed. Our findings must be considered in the context of the study s limitations. Although this is the largest trial in severe AAV, it has limited statistical power to reliably conclude whether there is a difference between and and is therefore at risk of failing to identify a clinically important benefit. This risk is increased by the loss of 15 patients to long-term with more patients in the group lost. This differential loss of may have introduced an unpredictable bias in the results. We believe this bias is, however, small in magnitude and unlikely to alter our conclusions. We cannot, however, conclude that no benefit exists. Further, is frequently considered in addition to rather than as an alternative to. This trial was also restricted to patients with a creatinine 4500 or on dialysis. If is effective, it is likely that it would also be effective in patients with rapidly progressive glomerulonephritis but a creatinine o500 mmol/l. This is also suggested by the finding that the patients with the least amount of chronic scarring on renal biopsy were the most likely to recover and from a meta-analysis of trials. 4,8 Finally, we are unable to inform the potential use of in relapses as this information was not collected. continues to be a promising therapy for AAV, but further trials are required to inform the potential for an increased risk of infections and death. This is particularly relevant given the invasiveness and cost of. The ongoing 500 patient PEXIVAS trial with up to 7 years of planned (ISRCTN ; clinicaltrials.gov NCT ) will improve our knowledge of the effect of on AAV. Even if is demonstrated an effective therapy for AAV, we will require further improvements in the care of patients with severe manifestations to reduce the current unacceptably high mortality and ESRD rates. Given the relative frequency of infectious causes of death, reducing this risk must be a priority in future studies. 400 Kidney International (2013) 84,
5 MATERIALS AND METHODS Study design The trial was conducted in accordance with the Declaration of Helsinki Principles, and the protocol is previously described and available online ( 3 Briefly, MEPEX was a two parallel limb, randomized control trial conducted in 28 hospitals in nine European countries. Informed consent was obtained for all patients and they were treated with the same regimen of oral cyclophosphamide for 6 months and with a tapering regimen of oral prednisolone. At trial entry, patients were randomly assigned to receive either or in addition to cyclophosphamide and prednisolone. was prescribed as seven exchanges of 5% albumin (in the absence of a risk for bleeding in which case plasma could be used) over 14 days at a volume of 60 ml/kg per exchange with an upper limit of 4.5 l per exchange. was prescribed as three doses of 1 g/day. Patients were maintained on azathioprine after 6 months of treatment. Patients Eligible patients had a diagnosis of granulomatosis polyangiitis or microscopic polyangiitis using criteria adapted from the Chapel Hill consensus conference, 9 biopsy evidence of pauci-immune, necrotizing and/or crescentic glomerulonephritis, and a serum creatinine 4500 mmol/l or required dialysis. Follow-up Patients were recruited between March 1995 and October The original trial lasted 12 months. Extended was conducted between October 2004 and November 2006, with clinical data abstracted to standardized data collection forms by local investigators. Outcomes The primary outcome for this analysis was the composite of ESRD or death from any cause. ESRD was defined as the need for permanent renal replacement therapy as determined by permanent dialysis dependence or receipt of a renal transplant. The composite was chosen, because death acts as a competing event for ESRD. Competing events are important to consider when the occurrence of one event that occurs frequently precludes the occurrence of the outcome of interest and, particularly, when the effect of treatment may be different on the competing event than the primary event of interest. 10 In this case, early deaths preclude the occurrence of ESRD (i.e., death competes for ESRD). We also assessed the occurrence of ESRD and death separately. Relapses of AAV were considered a secondary outcome. A relapse was defined as any new or worsened state of disease activity that required an escalation in treatment (immunosupressives and/or glucocorticoids). Renal function: Serum creatinine at 5 years after onset of disease was recorded in survivors not on dialysis. Statistics Descriptive data is presented as mean (s.d.) or median (25th to 75th percentile) for continuous variables and as frequency (%) for categorical data. The outcomes were assessed using time-to-event analyses. We assessed the primary composite outcome of ESRD or death with a standard Cox proportional hazard model. The Cox proportional hazard model was also used to assess the effect of on all-cause death. Analysis of ESRD incorporated the competing risk of death by calculating the subhazard for ESRD as a function of model covariates that were jointly fit to the hazard of death. 11 In both models, all-cause death was considered the competing risk, as patients that die before ESRD or relapse are unable to experience the event of interest (ESRD). Relapses were also assessed using the competing risk framework in which death was considered a competing risk. In addition, renal relapses were assessed using both death and ESRD as a competing risk. Sensitivity analyses adjusted for previously described risk factors for death and relapse: age, sex, diagnosis of granulomatosis with polyangiitis versus microscopic polyangiitis, and cytoplasmic antineutrophil cytoplasm antibody immunofluorescence/anti-pr3 antibodies (Supplementary Table S1 online). We did not adjust for serum creatinine given its uncertain prognostic value across the range included in this trial (i.e., all 4500 mmol/l). In models in which ESRD was an outcome, patients were right censored on the first day of dialysis without subsequent recovery. Renal function at 5 years was compared using analysis of covariance to account for the correlation between pretreatment and posttreatment correlations. Estimates of the effect of, their 95% CI, and associated P-values were calculated for each outcome. A two-tailed P-value o0.05 was considered significant for all analyses, with no adjustments made for multiple comparisons. All analyses were performed with Stata 11 MP (Stata, College Station, TX). DISCLOSURE MW and DRWJ are principle investigators of a trial that has in-kind support from Caridian BCT and Fresenius Australia for plasma exchange disposables. All the other authors declared no competing interests. ACKNOWLEDGMENTS This trial was supported by grants from the European League Against Rheumatism and by the European Union (European Community Systemic Vasculitis Trial project (BMH1-CT and CIDP-CT ) and Associated Vasculitis European Randomized Trial project (BMH4-CT and IC20-CT )). MW is supported by a Kidney Research Scientist Core Education National Training (KRESCENT) New Investigator Award from the Canadian Institutes of Health Research, Kidney Foundation of Canada, and the Canadian Society of Nephrology. DRWJ is supported by the Cambridge Biomedical Research Centre. CP is supported by the Imperial Biomedical Research Centre. SUPPLEMENTARY MATERIAL Table S1. Results of senstivity analyses adjusted for age, sex, disease activity, and antibody specificity. Supplementary Material is linked to the online version of the paper at REFERENCES 1. Flossmann O, Berden A, De GK et al. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis 2011; 70: Little MA, Nightingale P, Verburgh CA et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: Kidney International (2013) 84,
6 4. Walsh M, Catapano F, Szpirt W et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57: Keith DS, Nichols GA, Gullion CM et al. Longitudinal and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: Menahem S, Hiremagalur B, Mudge D et al. The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2008; 13(Suppl 2): S24 S Szczepiorkowski ZM, Bandarenko N, Kim HC et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17: Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007; 60: Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2: Kidney International (2013) 84,
Recent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationProtocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
More informationPlasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
More informationLong-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange: a retrospective, single-centre study
Frausová et al. Arthritis Research & Therapy (2016) 18:168 DOI 10.1186/s13075-016-1055-5 RESEARCH ARTICLE Open Access Long-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationRATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with
http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,
More informationOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective
More informationJones slide di 23
1 di 23 The patient with ANCA- associated vasculitis and pulmonary haemorrhage Rachel B Jones, Cambridge, UK Chairs:Hans-Joachim Anders, Munich, Germany Vladimir Tesar, Prague, Czech Republic Prof. Rachel
More informationEudraCT number: Page 8 of 42
EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Rituximab for treatment of severe renal disease in ANCA associated vasculitis Geetha, Duvuru; Hruskova, Zdenka; Segelmark, Marten; Hogan, Jonathan; Morgan, Matthew; Cavero, Teresa; Eriksson, Per; Seo,
More informationIntravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis
Article Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis Ruth J. Pepper,* Dimitrios Chanouzas, Ruth Tarzi, Mark A. Little,* Alina Casian, Michael Walsh,
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationfor the European Vasculitis Study Group submitted
Predictors of long-term ( 5 year) renal survival in 55 patients with ANCA-associated vasculitis Annelies Berden Oliver Floßmann Kerstin Westman Peter Höglund Chris Hagen Saskia le Cessie Michael Walsh
More informationAnnals of the Rheumatic Diseases 2011; 70(3):
Long-term patient survival in ANCA-associated vasculitis Oliver Floßmann Annelies Berden Kirsten de Groot Chris Hagen Lorraine Harper Caroline Heijl Peter Höglund David Jayne Raashid Luqmani Alfred Mahr
More informationEnd-stage renal disease in ANCA-associated vasculitis
Nephrol Dial Transplant (2017) 32: 248 253 doi: 10.1093/ndt/gfw046 Advance Access publication 6 April 2016 End-stage renal disease in ANCA-associated vasculitis Sergey Moiseev 1, Pavel Novikov 1, David
More informationCase Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationEudraCT number: Page 9 of 46
EudraCT number: 2012-001102-14 Page 9 of 46 5 Trial Synopsis Title Sponsor name North American Sponsor Japan Sponsor Ireland Sponsor Disease Under Investigation An international, open label, randomised,
More informationGlucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationTreatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2015;41:296301 Received: March 12, 2015 Accepted: May 6, 2015 Published online: June 2, 2015 Treatment
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationSponsored document from American Journal of Kidney Diseases
Sponsored document from American Journal of Kidney Diseases Prediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum Creatinine Clara J. Day
More informationANCA-associated vasculitis with renal involvement: an outcome analysis
NDT Advance Access published April 6, Nephrol Dial Transplant () 1 of 9 DOI: 1.193/ndt/gfh161 Original Article ANCA-associated vasculitis with renal involvement: an outcome analysis Sven Weidner 1, Steffen
More informationOptimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials
Prague Medical Report / Vol. 107 (2006) No. 2, p. 199 212 199) Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials Vaňková
More informationRate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationEstimating Renal Survival Using the ANCA-Associated GN Classification
Estimating Renal Survival Using the ANCA-Associated GN Classification Marc Hilhorst, Benjamin Wilde, Peter van Breda Vriesman, Pieter van Paassen, and Jan Willem Cohen Tervaert, for the Limburg Renal Registry
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More informationABSTRACT. n engl j med 363;3 nejm.org july 15,
The new england journal of medicine established in 1812 july 15, 21 vol. 363 no. 3 Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis Rachel B. Jones, M.R.C.P., M.D., Jan Willem Cohen
More informationImproved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies
Nephrol Dial Transplant (2015) 30: i67 i75 doi: 10.1093/ndt/gfv008 Advance Access publication 17 February 2015 Original Article Improved prognosis in Norwegian patients with glomerulonephritis associated
More informationClinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationRepeat protocol renal biopsy in ANCA-associated renal vasculitis
NDT Advance Access published February 26, 2014 Nephrol Dial Transplant (2014) 0: 1 5 doi: 10.1093/ndt/gfu042 Original Article Repeat protocol renal biopsy in ANCA-associated renal vasculitis Zdenka Hruskova
More informationPrediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum Creatinine
ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease Prediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum Creatinine Clara
More informationEarly plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis
Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis J.W. Gregersen 1, T. Kristensen 1, S.R.P. Krag 2, H. Birn 1, P. Ivarsen 1 1 Department of Nephrology, 2 Department of Pathology,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationAntineutrophil cytoplasm antibody associated vasculitis: recent developments
mini review http://www.kidney-international.org & 2013 International Society of Nephrology Antineutrophil cytoplasm antibody associated vasculitis: recent developments Shunsuke Furuta 1 and David R.W.
More informationRenal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationANCA-associated glomerulonephritis in the very elderly
http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 699 ANCA-associated glomerulonephritis in the very elderly Andrew S. Bomback 1, Gerald
More informationTRIALS. Walsh et al. Trials 2013, 14:73
Walsh et al. Trials 2013, 14:73 TRIALS STUDY PROTOCOL Open Access Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol
More informationEUVAS update June 5 th Marinka Twilt
EUVAS update June 5 th 2012 Marinka Twilt Chapel Hill 2012 Classification Large Vessel Vasculitis (LVV) Medium Vessel Vasculitis (MVV) Small Vessel Vasculitis (SVV) Variable Vessel Vasculitis (VVV) Single
More informationVascularites rénales associées aux ANCA
Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationSMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
More informationCombined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationRecurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression
original article http://www.kidney-international.org & 2007 International Society of Nephrology Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression
More informationWegener s Granulomatosis JUN-KI PARK
Wegener s Granulomatosis JUN-KI PARK Definition History Epidemiology Clinical symptoms Pathophysiology Treatment Wegener granulomatosis (WG) is a complex, immunemediated disorder, which along with microscopic
More informationRelation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
Houben et al. BMC Nephrology (2017) 18:378 DOI 10.1186/s12882-017-0797-x RESEARCH ARTICLE Open Access Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis Eline
More informationPredictors of Treatment Outcomes in ANCA-Associated Vasculitis with Severe Kidney Failure
Article Predictors of Treatment Outcomes in ANCA-Associated Vasculitis with Severe Kidney Failure Taewoo Lee,* Adil Gasim, Vimal K. Derebail,* Yunro Chung, JulieAnne G. McGregor,* Sophia Lionaki, Caroline
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014
TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE Loïc Guillevin Hôpital Cochin, Université Paris Descartes DU MALADIES SYSTEMIQUES, 7 March 2014 1 Disclosure of interest regarding this presentation Former
More informationPauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters?
International Journal of Rheumatic Diseases 2016; 19: 74 81 ORIGINAL ARTICLE Pauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters? Aman SHARMA, 1, * Ritambra
More informationAnti-neutrophil Cytoplasmic Antibody-associated Pauci-immune Crescentic Glomerulonephritis Complicating Sjögren s Syndrome
Volume 110 Number 7 July 2011 Enterovirus 71 vaccine: When will it be available? GRP78 in embryonic development and neurological disorders Directly observed therapy for Tuberculosis patients in Taiwan
More informationNew Developments in ANCA-associated Vasculitis
New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationPredictors of renal and patient outcomes in anti-gbm disease: clinicopathologic analysis of a two-centre cohort
NDT Advance Access published January 20, 2015 Nephrol Dial Transplant (2015) 0: 1 7 doi: 10.1093/ndt/gfu399 Original Article Predictors of renal and patient outcomes in anti-gbm disease: clinicopathologic
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationRenal transplantation in ANCA-associated vasculitis
Renal transplantation in ANCA-associated vasculitis Mårten Segelmark Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Mårten Segelmark, Renal
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationManagement of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe
Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationTITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness
TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness DATE: 28 January 2015 CONTEXT AND POLICY ISSUES Granulomatosis with polyangiitis
More informationEvidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes
associo far? Evidence-based therapy for the ANCAassociated vasculitides: what do the trials show so far? Anti-neutrophil cytoplasm antibody-associated vasculitides are rare multisystem inflammatory diseases
More informationCombination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 21 22 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 41 42 43 44 45 46 47 48 49 5 51 Combination Therapy With Rituximab and Cyclophosphamide for Remission
More informationAnti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease
Anti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease Grace M. Lee, Yara A. Park, Marshall Mazepa, Jay S. Raval Introduction Anti-neutrophil
More informationVasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis
Edward Dwyer, M.D. Division of Rheumatology VASCULITIS is a primary inflammatory disease process of the vasculature Determinants of the Clinical Manifestations of : Target organ involved Size of vessel
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
Clinical Kidney Journal, 2017, vol. 10, no. 4, 470 474 doi: 10.1093/ckj/sfx014 Advance Access Publication Date: 12 April 2017 Original Article ORIGINAL ARTICLE Immunoglobulin levels and infection risk
More informationClinical features and outcome of patients with both ANCA and anti-gbm antibodies
Kidney International, Vol. 66 (24), pp. 1535 154 Clinical features and outcome of patients with both ANCA and anti-gbm antibodies JEREMY B. LEVY, TARIG HAMMAD, ANNE COULTHART, TAMMY DOUGAN, and CHARLES
More informationTechnology appraisal guidance Published: 26 March 2014 nice.org.uk/guidance/ta308
Rituximab in combination with glucocorticoids for treating antineutrophil cytoplasmic antibody- associated vasculitis Technology appraisal guidance Published: 26 March 2014 nice.org.uk/guidance/ta308 NICE
More informationOutcome of Kidney Transplant in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
ARTIcLe Outcome of Kidney Transplant in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Jesmar Buttigieg, 1 Lorna Henderson, 2 Dana Kidder 1 Abstract From the 1 Renal Unit, Aberdeen Royal Infirmary,
More informationThe Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage
CASE REPORT The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage Kimihiko Goto, Kentaro Nakai, Hideki Fujii and Shinichi Nishi Abstract Antineutrophil cytoplasmic autoantibody
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationA new approach to conducting randomized clinical trials in the community setting.
A new approach to conducting randomized clinical trials in the community setting. IRB # Pro00013241 The TAPIR trial is sponsored by: Vasculitis Clinical Research Consortium (VCRC) National Heart Lung and
More informationSeizure remission in adults with long-standing intractable epilepsy: An extended follow-up
Epilepsy Research (2010) xxx, xxx xxx journal homepage: www.elsevier.com/locate/epilepsyres Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up Hyunmi Choi a,, Gary
More informationNew and Emerging Technology Briefing. Fibrillex (Eprodisate disodium) for secondary amyloidosis. National Horizon Scanning Centre.
New and Emerging Technology Briefing National Horizon Scanning Centre Fibrillex (Eprodisate disodium) for secondary amyloidosis January 2006 Horizon Scanning Review Early assessments of new or emerging
More informationThe European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France
The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,
More informationReview Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar
Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil
More informationIntravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Int Urol Nephrol (2013) 45:1301 1308 DOI 10.1007/s11255-012-0331-9 NEPHROLOGY - ORIGINAL PAPER Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis Prayong Vachvanichsanong
More informationRenal transplantation
NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible
More informationNIH Public Access Author Manuscript Ann Rheum Dis. Author manuscript; available in PMC 2011 July 19.
NIH Public Access Author Manuscript Published in final edited form as: Ann Rheum Dis. 2009 January ; 68(1): 103 106. doi:10.1136/ard.2008.097758. Comparison of disease activity measures for anti-neutrophil
More informationIncidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort
Nephrol Dial Transplant (21) 25: 223 229 doi: 1.193/ndt/gfq11 Advance Access publication 2 February 21 Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort Jean-Philippe
More informationVascularites associées aux ANCA Traitement par le RITUXIMAB
Vascularites associées aux ANCA Traitement par le RITUXIMAB Philippe Vanhille Néphrologie Médecine Interne Hôpital de Valenciennes Aix- en- Provence 2013 Cyclophosphamide therapy of severe systemic necrotizing
More informationRenal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement
Kidney International, Vol. 63 (2003), pp. 670 677 Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement MARJAN C. SLOT, JAN WILLEM COHEN TERVAERT,
More informationRenal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis
Nephrol Dial Transplant (2015) 30: i159 i163 doi: 10.1093/ndt/gfu328 Advance Access publication 16 October 2014 Full Review Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis
More informationAntineutrophil cytoplasmic antibody (ANCA) associated. Article
Annals of Internal Medicine Article Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody Associated Small-Vessel Vasculitis Susan L. Hogan, PhD, MPH; Ronald J. Falk, MD;
More informationThe systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.
60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,
More informationDisease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia
International Journal of Clinical Rheumatology Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia Background: ANCA-associated vasculitis (AAV) is a potentially
More informationSmall Vessel Vasculitis
Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk
More informationVASCULITIS. Case Presentation. Case Presentation
VASCULITIS Case Presentation The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have
More informationRituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
NIHR Innovation Observatory Evidence Briefing: August 2017 Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) NIHRIO (HSRIC) ID: 12979
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationClinical research in adult vasculitis. Calgary October 8 th, 2015
Clinical research in adult vasculitis Calgary October 8 th, 2015 Disclosures Consulting and speaker fees Hoffmann-La Roche BMS Advisory boards Hoffmann-La Roche GSK Educational subventions (CanVasc) Hoffmann-La
More informationSimple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis
Haris et al. BMC Nephrology (2017) 18:76 DOI 10.1186/s12882-017-0491-z RESEARCH ARTICLE Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis
More information